

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Biostime International Holdings Limited**

**合生元國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1112)**

**COMPLETION OF THE VERY SUBSTANTIAL ACQUISITION AND  
CONNECTED TRANSACTION IN RELATION  
TO THE ACQUISITION OF THE REMAINING  
APPROXIMATELY 17% EQUITY INTEREST  
IN BIOSTIME AUSTRALIA HOLDINGS**

Unless otherwise defined in this announcement, terms defined in the announcement dated 15 December 2016 (the “**Announcement**”) issued by Biostime International Holdings Limited (the “**Company**”) have the same meanings when used in this announcement.

The Board is pleased to announce that all the conditions precedent to the 17% Acquisition as stated in the Announcement have been fulfilled and completion of the 17% Acquisition took place on 7 February 2017. As a result, the Company’s equity interest in Biostime Australia Holdings has increased from approximately 83% to 100%, and the financial information of the BAH Group will continue to be consolidated into the accounts of the Group.

By order of the Board  
**Biostime International Holdings Limited**  
**Luo Fei**  
*Chairman*

Hong Kong, 7 February 2017

*As at the date of this announcement, the executive Director of the Company is Mr. Luo Fei; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.*